by The global CAR T-cell therapy market size accounted for US$ 2.19 Bn in 2022 and is projected to reach around USD 6.43 Bn by 2032, growing at a CAGR of 11.37% from 2023 to 2032.
Report Summary
The global CAR T-cell therapy market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the CAR T-cell therapy market across the globe.
A comprehensive estimate on the CAR T-cell therapy market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of CAR T-cell therapy during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2545
CAR T-Cell Therapy Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 2.44 Billion |
| Market Size by 2032 | USD 6.43 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 11.37% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Drug Type, By Indication and By End User |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized CAR T-cell therapy market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Newborn Eye Imaging Systems Market Size Analysis 2023 To 2032
CAR T-Cell Therapy Market Players
The report includes the profiles of key CAR T-cell therapy market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- Kolon TissueGene, Inc.
- JCR Pharmaceuticals Co., Ltd.
- Kolon TissueGene, Inc.
- JCR Pharmaceuticals Co., Ltd.
- MEDIPOST
- PHARMICELL Co., Ltd.
- ANTEROGEN. CO., LTD
- Bristol-Myers Squibb Company
- Novartis AG
- Gilead Sciences, Inc.
- Curocell, Inc.
- JW Therapeutics (Shanghai) Co., Ltd.
- Stempeutics Research PVT LTD
Market Segmentation
By Drug Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia (CLL)
- Multiple Myeloma (MM)
- Others
By End User
- Hospitals
- Cancer Treatment Centers
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on CAR T-Cell Therapy Market
5.1. COVID-19 Landscape: CAR T-Cell Therapy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global CAR T-Cell Therapy Market, By Drug Type
8.1. CAR T-Cell Therapy Market, by Drug Type, 2022-2032
8.1.1 Axicabtagene Ciloleucel
8.1.1.1. Market Revenue and Forecast (2022-2032)
8.1.2. Tisagenlecleucel
8.1.2.1. Market Revenue and Forecast (2022-2032)
8.1.3. Brexucabtagene Autoleucel
8.1.3.1. Market Revenue and Forecast (2022-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2022-2032)
Chapter 9. Global CAR T-Cell Therapy Market, By Indication
9.1. CAR T-Cell Therapy Market, by Indication, 2022-2032
9.1.1. Lymphoma
9.1.1.1. Market Revenue and Forecast (2022-2032)
9.1.2. Acute Lymphocytic Leukemia
9.1.2.1. Market Revenue and Forecast (2022-2032)
9.1.3. Chronic Lymphocytic Leukemia (CLL)
9.1.3.1. Market Revenue and Forecast (2022-2032)
9.1.4. Multiple Myeloma (MM)
9.1.4.1. Market Revenue and Forecast (2022-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2022-2032)
Chapter 10. Global CAR T-Cell Therapy Market, By End User
10.1. CAR T-Cell Therapy Market, by End User, 2022-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2022-2032)
10.1.2. Cancer Treatment Centers
10.1.2.1. Market Revenue and Forecast (2022-2032)
Chapter 11. Global CAR T-Cell Therapy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.1.2. Market Revenue and Forecast, by Indication (2022-2032)
11.1.3. Market Revenue and Forecast, by End User (2022-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.1.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.1.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.1.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.1.5.3. Market Revenue and Forecast, by End User (2022-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.2.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.3. Market Revenue and Forecast, by End User (2022-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.2.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.2.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.5.3. Market Revenue and Forecast, by End User (2022-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.2.6.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.6.3. Market Revenue and Forecast, by End User (2022-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.2.7.2. Market Revenue and Forecast, by Indication (2022-2032)
11.2.7.3. Market Revenue and Forecast, by End User (2022-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.3.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.3. Market Revenue and Forecast, by End User (2022-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.3.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.3.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.5.3. Market Revenue and Forecast, by End User (2022-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.3.6.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.6.3. Market Revenue and Forecast, by End User (2022-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.3.7.2. Market Revenue and Forecast, by Indication (2022-2032)
11.3.7.3. Market Revenue and Forecast, by End User (2022-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.4.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.4.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.5.3. Market Revenue and Forecast, by End User (2022-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.4.6.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.6.3. Market Revenue and Forecast, by End User (2022-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.4.7.2. Market Revenue and Forecast, by Indication (2022-2032)
11.4.7.3. Market Revenue and Forecast, by End User (2022-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.5.3. Market Revenue and Forecast, by End User (2022-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.5.4.2. Market Revenue and Forecast, by Indication (2022-2032)
11.5.4.3. Market Revenue and Forecast, by End User (2022-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2022-2032)
11.5.5.2. Market Revenue and Forecast, by Indication (2022-2032)
11.5.5.3. Market Revenue and Forecast, by End User (2022-2032)
Chapter 12. Company Profiles
12.1. Kolon TissueGene, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. JCR Pharmaceuticals Co., Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Kolon TissueGene, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. JCR Pharmaceuticals Co., Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. MEDIPOST
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. PHARMICELL Co., Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. ANTEROGEN. CO., LTD
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bristol-Myers Squibb Company
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Novartis AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Gilead Sciences, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
